Thanks Lobo Solitario. The treatment obviously appears to work as intended. I'm guessing the survival duration and progression-free survival rate would be even higher if patients were given the treatment a little earlier. The 70% reduced blood flow to the tumors shows it was working; it just didn't have enough time to complete its work for many of the patients.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.